ストックスクリーナーアプリを入手
3.57
1.13%
0.04
前日終値:
$3.53
開ける：
$3.6
24時間の取引高:
3.55M
Relative Volume:
7.04
時価総額：
$843.31M
収益：
$4.90M
当期純損益:
$-399.99M
株価収益率:
-1.2567
EPS:
-2.8407
ネットキャッシュフロー:
$-122.90M
1週間 パフォーマンス:
-6.05%
1か月 パフォーマンス:
-28.88%
6か月 パフォーマンス:
-15.00%
1年 パフォーマンス:
+6.28%
1日の値動き範囲:
$3.525
$3.61
1週間の範囲:
$3.49
$3.97
52週間の値動き範囲:
$2.8536
$7.9825
Inventiva Adr Stock (IVA) Company Profile
Compare IVA vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IVA
Inventiva Adr
|
3.57 | 843.31M | 4.90M | -399.99M | -122.90M | -2.8407 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inventiva Adr Stock (IVA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-19 | 開始されました | Truist | Buy |
| 2026-01-28 | 開始されました | Barclays | Overweight |
| 2026-01-12 | 開始されました | Leerink Partners | Outperform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-06 | 開始されました | Wolfe Research | Outperform |
| 2025-09-03 | 再開されました | H.C. Wainwright | Buy |
| 2025-08-27 | 開始されました | Piper Sandler | Overweight |
| 2025-02-21 | 開始されました | TD Cowen | Buy |
| 2024-11-12 | 開始されました | UBS | Neutral |
| 2023-10-27 | 開始されました | Canaccord Genuity | Buy |
| 2023-05-31 | 開始されました | ROTH MKM | Buy |
| 2023-05-19 | アップグレード | Societe Generale | Sell → Buy |
| 2023-03-17 | 開始されました | Stifel | Buy |
| 2022-11-15 | ダウングレード | Societe Generale | Buy → Sell |
| 2021-03-08 | ダウングレード | Societe Generale | Buy → Sell |
| 2020-08-05 | 開始されました | ROTH Capital | Buy |
| 2020-08-04 | 開始されました | Guggenheim | Buy |
| 2020-08-04 | 開始されました | Stifel | Buy |
すべてを表示
Inventiva Adr (IVA) 最新ニュース
Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development - GlobeNewswire Inc.
Down 31.8% in 4 weeks, here's why Inventiva (IVA) looks ripe for a turnaround - MSN
Down 31.8% in 4 Weeks, Here's Why Inventiva (IVA) Looks Ripe for a Turnaround - Yahoo Finance
Super Micro Computer, Summit Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Sahm
IVA SEC FilingsInventiva S.A. 10-K, 10-Q, 8-K Forms - Stock Titan
Here's Why Inventiva (IVA) Is a Great 'Buy the Bottom' Stock Now - MSN
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Phreesia, Service Properties Trust, Inventiva and other big stocks moving lower in Tuesday's pre-market session - MSN
Inventiva (NASDAQ:IVA) Sees Large Volume IncreaseHere's What Happened - MarketBeat
Phreesia, Service Properties Trust, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Short Interest Update - MarketBeat
Zenas Biopharma, Daqo New Energy and other big stocks moving lower in Friday's pre-market session - MSN
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Does Inventiva (IVA) have the potential to rally 136.34% as Wall Street analysts expect? - MSN
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Sahm
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $17.00 Consensus PT from Brokerages - Defense World
Short Interest in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Drops By 20.4% - MarketBeat
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Average Rating of "Buy" from Analysts - MarketBeat
Does Inventiva (IVA) Have the Potential to Rally 136.34% as Wall Street Analysts Expect? - Finviz
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Inventiva CEO: Phase 3 Lanifibranor MASH Trial Fully Enrolled, Top-Line Data Due in H2 - Yahoo Finance
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Sees Significant Increase in Short Interest - MarketBeat
Are You Looking for a Top Momentum Pick? Why Inventiva S.A. Sponsored ADR (IVA) is a Great Choice - Yahoo Finance
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives Consensus Rating of “Buy” from Analysts - Defense World
Inventiva SA ADR Trade Ideas — LSX:A2P796 - TradingView
Inventiva (NASDAQ:IVA) Shares Gap Up on Analyst Upgrade - Defense World
Inventiva’s (IVA) “Buy” Rating Reiterated at UBS Group - Defense World
Wall Street Analysts Predict a 200.59% Upside in Inventiva (IVA): Here's What You Should Know - primepublishers.com
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Inventiva (NASDAQ:IVA) Sees Strong Trading VolumeHere's Why - MarketBeat
Why Heartbeam Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket - Benzinga
Novo Nordisk, Waldencast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Inventiva Stock Falls 9% Following Announcement of a Dilutive Financing Program - Idéal Investisseur
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Inventiva SA Reports Progress and Challenges in 2025 - The Globe and Mail
Inventiva, MoonLake Immunotherapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Inventiva Adr (IVA) 財務データ
収益
当期純利益
現金流量
EPS
0.74%
1.44%
大文字化:
|
ボリューム (24 時間):